Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor necrosis factor (TNF) is a proinflammatory cytokine existing in soluble and membrane-bound forms. When TNF binds to TNF receptors, it triggers NF-κB activation, T-cell activation, and leukocyte infiltration, causing transmural inflammation characteristic of Crohn's disease. This central role in inflammation makes TNF a prime therapeutic target for disease management.

Anti-TNF monoclonal antibodies like infliximab, adalimumab, and golimumab bind to TNF and block its interaction with TNF receptors, preventing inflammatory cellular responses. Their Fc portion promotes antibody-mediated apoptosis of activated immune cells, effectively curbing inflammation and leading to symptomatic improvement and remission in Crohn's disease patients.

Infliximab, adalimumab, and golimumab are IgG1 monoclonal antibodies with intact Fc portions. Certolizumab is a recombinant antibody lacking the Fc portion, instead featuring a Fab fragment conjugated to polyethylene glycol (PEG). These structural variations influence their administration routes, immunological properties, and clinical efficacy in treating Crohn's disease.

Infliximab is administered via intravenous infusions, allowing direct systemic delivery into the bloodstream. Adalimumab, golimumab, and certolizumab are given subcutaneously, enabling patients to self-administer treatment at home. The route of administration depends on the drug's molecular structure and pharmacokinetic properties.

Anti-TNF agents can cause serious infections including bacterial sepsis, tuberculosis, and hepatitis B reactivation because TNF plays a critical role in immune defense. Additionally, patients may experience infusion reactions such as fever, headache, and chest pain, requiring careful clinical monitoring during and after treatment administration.

TNF-receptor interaction triggers multiple inflammatory pathways including NF-κB signaling, T-cell activation, and leukocyte infiltration, all contributing to transmural inflammation in Crohn's disease. By targeting TNF with monoclonal antibodies, clinicians can interrupt these cascading inflammatory responses and significantly reduce disease severity and symptoms.

Anti-TNF biologic agents represent a targeted immunological approach to Crohn's disease management by directly neutralizing a key inflammatory mediator. Other treatment options like drugs for treatment of crohn s disease in ibd using glucocorticoids work through different mechanisms, offering complementary therapeutic strategies for managing inflammatory bowel disease.